"I can't even say this without getting a little teary." Watch Dr. Priscilla Chan talk about the FOXG1 Research Foundation’s gene therapy on Stanford Medicine's "The Future of Medicine."

FOXG1 families and Foundation leadership visited the Rockville CDMO site at Charles River Laboratories — where our gene therapy is being manufactured.

We saw firsthand the precision, safeguards, and care behind plasmid and AAV vector production, and the responsibility carried at every step.

The FOXG1 Research Foundation has named Brandon M. Henry, M.D., as Chief Medical Officer as FRF-001 advances toward a first-in-human clinical trial. Dr. Henry brings deep experience in AAV gene therapy development and will lead clinical strategy and oversight as we prepare to move into patient clinical trials.

The FOXG1 Research Foundation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FRF-001 for the treatment of FOXG1 syndrome — marking another major regulatory milestone as we advance toward our first-in-human Phase 1/2 clinical trial.

The FOXG1 Research Foundation announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin first-in-human clinical trials for FRF-001, the first FOXG1 AAV9 gene replacement therapy.